This is BrainsWay’s global website. The global website is not intended for persons in the United States and includes information on clinical indications that were not cleared by the FDA, which are subject to further US regulatory review for safety and efficacy. BrainsWay is cleared by the FDA only for patients with MDD who failed to respond to one or more anti-depressants in the current episode, and for patients with OCD as an adjunct treatment.
Through modern day, therapies and medication to treat OCD have been extremely limited. Now, BrainsWay’s Deep Transcranial Magnetic Stimulation system can over hope to OCD patients, with over 50% of patient seeing meaningful reduction in severity of OCD symptoms.